Literature DB >> 20647475

Targeting cell division cycle 7 kinase: a new approach for cancer therapy.

Alessia Montagnoli1, Jürgen Moll, Francesco Colotta.   

Abstract

The cell division cycle 7 (Cdc7) is a serine-threonine kinase, originally discovered in budding yeast, required to initiate DNA replication. Human Cdc7 phosphorylates the minichromosome maintenance protein 2 (Mcm2), a component of the DNA replicative helicase needed for genome duplication. Inhibition of Cdc7 in cancer cells impairs progression through S phase, inducing a p53-independent apoptotic cell death, whereas in normal cells, it does not affect cell viability. Small molecule compounds able to interfere with Cdc7 activity have been identified and shown to be effective in controlling tumor growth in animal models. Two Cdc7 inhibitors are currently in phase I clinical development. Inhibition of Cdc7 kinase activity in cancer cells restricts DNA replication and induces apoptotic cell death by an unprecedented molecular mechanism of action. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647475     DOI: 10.1158/1078-0432.CCR-10-0185

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  53 in total

1.  Cell division cycle 7 is a novel regulator of transforming growth factor-β-induced smooth muscle cell differentiation.

Authors:  Ning Shi; Wei-Bing Xie; Shi-You Chen
Journal:  J Biol Chem       Date:  2012-01-05       Impact factor: 5.157

Review 2.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

3.  Crystal structure of human CDC7 kinase in complex with its activator DBF4.

Authors:  Siobhan Hughes; Frédéric Elustondo; Andrea Di Fonzo; Frédéric G Leroux; Ai C Wong; Ambrosius P Snijders; Stephen J Matthews; Peter Cherepanov
Journal:  Nat Struct Mol Biol       Date:  2012-10-14       Impact factor: 15.369

4.  Subcellular proteomics reveals a role for nucleo-cytoplasmic trafficking at the DNA replication origin activation checkpoint.

Authors:  Claire M Mulvey; Slavica Tudzarova; Mark Crawford; Gareth H Williams; Kai Stoeber; Jasminka Godovac-Zimmermann
Journal:  J Proteome Res       Date:  2013-02-06       Impact factor: 4.466

5.  Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells.

Authors:  Yun Hou; Hua-Qing Wang; Yi Ba
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-18       Impact factor: 4.553

6.  Comparison of luminescence ADP production assay and radiometric scintillation proximity assay for Cdc7 kinase.

Authors:  Toshimitsu Takagi; David Shum; Monika Parisi; Ruth E Santos; Constantin Radu; Paul Calder; Zahra Rizvi; Mark G Frattini; Hakim Djaballah
Journal:  Comb Chem High Throughput Screen       Date:  2011-09       Impact factor: 1.339

7.  Transcriptome analysis of neoplastic hemocytes in soft-shell clams Mya arenaria: Focus on cell cycle molecular mechanism.

Authors:  Ahmed Siah; Patty McKenna; Franck C J Berthe; Luis O B Afonso; Jean-Michel Danger
Journal:  Results Immunol       Date:  2013-11-01

8.  3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors.

Authors:  Mika Lindvall; Christopher McBride; Maureen McKenna; Thomas G Gesner; Asha Yabannavar; Kent Wong; Song Lin; Annette Walter; Cynthia M Shafer
Journal:  ACS Med Chem Lett       Date:  2011-08-02       Impact factor: 4.345

9.  High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.

Authors:  Yun Hou; Hua-Qing Wang; Yi Ba
Journal:  Med Oncol       Date:  2012-04-19       Impact factor: 3.064

10.  p53 gain-of-function mutations increase Cdc7-dependent replication initiation.

Authors:  Arindam Datta; Dishari Ghatak; Sumit Das; Taraswi Banerjee; Anindita Paul; Ramesh Butti; Mahadeo Gorain; Sangeeta Ghuwalewala; Anirban Roychowdhury; Sk Kayum Alam; Pijush Das; Raghunath Chatterjee; Maitrayee Dasgupta; Chinmay Kumar Panda; Gopal C Kundu; Susanta Roychoudhury
Journal:  EMBO Rep       Date:  2017-09-08       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.